N
N. Shore
Researcher at University of Alberta
Publications - 16
Citations - 5668
N. Shore is an academic researcher from University of Alberta. The author has contributed to research in topics: Prostate cancer & Enzalutamide. The author has an hindex of 11, co-authored 16 publications receiving 4992 citations.
Papers
More filters
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Silke Gillessen,Aurelius Omlin,Gerhardt Attard,J.S. de Bono,Eleni Efstathiou,Eleni Efstathiou,Eleni Efstathiou,Karim Fizazi,Susan Halabi,Peter S. Nelson,Oliver Sartor,Matthew R. Smith,Howard R. Soule,Hideyuki Akaza,Tomasz M. Beer,Himisha Beltran,Arul M. Chinnaiyan,Gedske Daugaard,Ian D. Davis,M. De Santis,Charles G. Drake,Rosalind A. Eeles,Stefano Fanti,Martin E. Gleave,Axel Heidenreich,Maha Hussain,Nicholas D. James,Nicholas D. James,Frédéric Lecouvet,Christopher J. Logothetis,Ken Mastris,Sten Nilsson,William Oh,David Olmos,Anwar R. Padhani,Chris Parker,Mark A. Rubin,Jack A. Schalken,Howard I. Scher,Howard I. Scher,Avishay Sella,N. Shore,Eric J. Small,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher Sweeney,Ian F. Tannock,Bertrand Tombal +47 more
TL;DR: The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed available evidence for the ten most important areas of controversy in advanced prostate cancer management.
Journal ArticleDOI
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg,Karim Fizazi,Fred Saad,N. Shore,Ugo De Giorgi,David F. Penson,Ubirajara Ferreira,Eleni Efstathiou,Katarzyna Madziarska,Michael Kolinsky,Daniel I.G. Cubero,Bettina Noerby,Fabian Zohren,Xun Lin,Katharina Modelska,Jennifer Sugg,Joyce Steinberg,Maha Hussain +17 more
TL;DR: Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgens-depRIvation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level.
Journal ArticleDOI
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
Allan Lipton,Karim Fizazi,Alison Stopeck,David H. Henry,Matthew R. Smith,N. Shore,Miguel Martin,Saroj Vadhan-Raj,Janet E. Brown,Gary Richardson,Fred Saad,Denise A. Yardley,K. Zhou,Arun Balakumaran,Ada Braun +14 more
TL;DR: Denosumab was superior to ZA in preventing SREs in patients with bone metastases from advanced cancer, regardless of ECOG PS, bone metastasis number, baseline visceral metastasis presence/absence, and uNTx level.
Journal ArticleDOI
PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Maha Hussain,Joaquin Mateo,Karim Fizazi,Fred Saad,N. Shore,Shahneen Sandhu,Kim N. Chi,Oliver Sartor,Neeraj Agarwal,David Olmos,Antoine Thiery-Vuillemin,Przemyslaw Twardowski,Niven Mehra,C. Goessl,Jinyu Kang,J. Burgents,W. Wu,Alexander Kohlmann,Carrie A. Adelman,J.S. de Bono +19 more